Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

3SBio Growth Driven By EPO With Shaky Future

This article was originally published in PharmAsia News

Executive Summary

Concerns raised by 3SBio's announcement of development delays for additional indications of its lead product EPIAO (recombinant human erythropoietin injection) are overshadowed by the product's growth potential, according to analysts

You may also be interested in...



3SBio Files For Approval For Interleukin-2 NuLeusin

SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced

3SBio Files For Approval For Interleukin-2 NuLeusin

SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced

3SBio CEO Jing Lou On Building An Integrated Biopharma Company In China: An Interview With PharmAsia News

Shenyang Sunshine Pharmaceutical Company Limited, now known as 3SBio, was incorporated in 1993 in Shenyang, China, and was the first Chinese biotech company to list on NASDAQ. The company develops and manufactures recombinant protein-based products, including erythropoietin stimulating agents such as the firm's flagship product EPIAO. 3SBio CEO and co-founder Jing Lou spoke recently with PharmAsia News' Shanghai bureau about building an integrated biopharmaceutical company in China, and the opportunities and challenges of competing in the global market.

UsernamePublicRestriction

Register

SC067726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel